Company intelligence / Profile preview
Aphios Pharma
- Ownership
- Private
- Employees
- ~25
- Development stage
- Other
Overview
Aphios and its subsidiaries are developing therapeutics ranging from completed Phase II/III clinical trials (Zindol for nausea and vomiting) to Phase I/II (APH-0703 for Alzheimer’s); other pipeline programs are pre-clinical or entering trials for chronic pain, addiction, HIV, and pathogen reduction in biologics, with enabling nanotechnology platforms validated via collaborations and grants[1][2][4].
- Therapeutic areas
- Women's HealthInfectious DiseasesNeurologyPsychiatryOncology
- Modalities
- Small moleculeNanoparticleBiologicsiRNAMonoclonal antibodyCannabis-based drug
- Industry
- Biotech
Drug pipeline
4 assets3 more assets in the full pipeline.
Request access →Partnerships
Beyond the preview
Go deeper on Aphios Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Aphios Pharma.